✅ Medical & Pharmaceutical Updated July 2026

CVS Caremark Lawsuits: Pharmacy Benefit Manager Pricing and Access Claims

Pharmacy benefit manager litigation concerns rebate structures, spread pricing, fees charged back to pharmacies, and formulary decisions that limit patient access.

Category

Medical & Pharmaceutical

Coverage

2025-2026

Last Updated

July 2026

Content Type

Legal Analysis

What a PBM Does

Pharmacy benefit managers sit between drug manufacturers, insurers and pharmacies. They negotiate rebates, decide which drugs appear on a formulary and at what tier, and set what pharmacies are reimbursed.

That intermediary position is the source of the litigation. The same organisation influences what a plan pays, what a pharmacy receives and what a patient is charged, and the differences between those figures are what claims focus on.

ℹ️

Spread pricing explained

Spread pricing is where a PBM charges a health plan more for a drug than it reimburses the pharmacy, retaining the difference. State enforcement actions have targeted whether that spread was disclosed to the plans paying it.

Rebate claims allege manufacturer rebates negotiated on list price created an incentive toward higher list prices, with patients whose costs are calculated on list price bearing the consequence at the counter.

Pharmacy claims concern reimbursement below acquisition cost and fees recouped after the fact, which independent pharmacies argue makes dispensing certain prescriptions loss-making.

Patient access claims concern formulary exclusions and step therapy requirements that oblige a patient to fail on a cheaper drug before a prescribed one is covered.

What Patients Can Do

If a medication is denied or excluded, request the formulary exception process in writing with prescriber support explaining why alternatives are unsuitable. Plans must maintain such a process and respond within set timeframes.

Compare the cash price against your copay, since for some generics the cash or discount card price is lower than the insured copay. Ask the pharmacist directly, as this is often not volunteered.

Gag clauses are prohibited

Federal law prohibits contract terms preventing a pharmacist from telling you that paying cash would cost less than your insurance copay. If you ask, they are permitted to tell you.

Free Legal Evaluation

Do You Qualify to File a Claim?

Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.

cvs caremark lawsuit Pharmacy Benefits Drug Pricing Insurance

CVS Caremark Lawsuits: Pharmacy Benefit Manager Pricing and Access Claims: Frequently Asked Questions

Answers to the most common questions about this case and your legal options.

What is a pharmacy benefit manager?

An intermediary that negotiates drug rebates, sets formularies and tiers, and determines pharmacy reimbursement between manufacturers, insurers and pharmacies.

What is spread pricing?

Charging a health plan more for a drug than the PBM reimburses the pharmacy, keeping the difference. Enforcement has focused on whether the spread was disclosed.

What are the main claims?

Rebate structures allegedly inflating list prices, pharmacy reimbursement below acquisition cost, and formulary exclusions or step therapy limiting patient access.

What if my medication is excluded?

Request the formulary exception process in writing with prescriber support. Plans must maintain such a process and respond within set timeframes.

Can a pharmacist tell me if cash is cheaper?

Yes. Federal law prohibits gag clauses preventing pharmacists from disclosing that the cash price is lower than your copay, so ask.

LawsuitWatch Legal Research Team

Medical & Pharmaceutical Litigation Desk

The LawsuitWatch Legal Research Team monitors federal court PACER filings, MDL docket activity, regulatory enforcement actions, and legal settlements to deliver accurate, timely coverage of litigation affecting American consumers. Content is reviewed for factual accuracy before publication and updated as cases develop. Last reviewed: July 2026.